TOURISE Announces Cross-Sector Advisory Board to Champion Bold New Platform Rewriting the Rules of Tourism
4.8.2025 21:53:00 EEST | Business Wire | Press release
TOURISE, the bold new global tourism platform, has announced the members of its cross-sector Advisory Board, a powerhouse of industry titans guiding TOURISE’s strategic direction and shaping the agenda of the inaugural global summit taking place in Riyadh from 11-13 November, 2025.
TOURISE is where cross-sector convergence begins, a platform where leaders and visionaries debate, collaborate and take action to shape the future of tourism.
The 14-member board brings together expertise from tourism, technology, aviation, entertainment, education, sustainability and media, making it one of the most intentionally cross-sector bodies in global tourism today. Together, they will champion TOURISE’s vision, ensure high-impact global issues such as equity, geographical representation and sectoral diversity are in spotlight and influence the long-term value of the platform.
Chaired by His Excellency Ahmed Al-Khateeb, Minister of Tourism of Saudi Arabia, the Advisory Board represents an alliance of cross-industry leaders, assembled to elevate tourism on the global stage and shape a bold new vision for the sector’s future.
“TOURISE is driving cross-sector global collaboration, and the formation of the Advisory Board ensures we are uniting diverse perspectives from representatives across the global tourism ecosystem,” His Excellency Ahmed Al-Khateeb said.
“Their visionary thinking and deep expertise will be essential in transforming TOURISE from ambition into action, ensuring the platform becomes a catalyst of innovation, investment, and sustainability in tourism for decades to come.”
The TOURISE Advisory Board members are:
- Julia Simpson, President & CEO, World Travel & Tourism Council.
- Randy Durband, CEO, Global Sustainable Tourism Council.
- Luis Maroto, CEO, Amadeus.
- Blake Chandlee, former President of Global Business Solutions, TikTok.
- Neil Jacobs, Founder of Wild Origins and former CEO of Six Senses.
- Stephane Lefebvre, President, Cirque du Soleil Entertainment Group.
- Jordi Carnes, President of Leitat Technological Center and CTECNO and former Director General of Turismede Barcelona.
- Mario Enzesberger, Founder and CEO, Liberty International Tourism Group.
- Patrick Andersen, CEO, Carlson Wagonlit Travel.
- Mo Gawdat, Founder, One Billion Happy.
- Thomas Woldbye, CEO, Heathrow Airport.
- Fahd Hamidaddin, CEO, Saudi Tourism Authority and Vice Chair, TOURISE.
- Fabien Fresnel, CEO, Riyadh School of Tourism and Hospitality.
- Jean-Philippe Cossé,International Events Specialist.
Julia Simpson, WTTC President & CEO said, “TOURISE is more than a summit; it’s a catalyst for global transformation in tourism. I joined the Advisory Board because I believe in the power of cross-sector collaboration to drive sustainable growth, foster innovation, and set new standards for responsible travel.”
Leading up to the TOURISE summit the Advisory Board will meet regularly to advise on the TOURISE program, ensuring global views and insights shape the agenda. Their stewardship ensures that TOURISE isn’t just a moment, it’s a movement.
For more information on TOURISE, the Advisory Board, or to register your interest in attending TOURISE, visit www.tourise.com
About TOURISE
TOURISE is the world’s premier platform shaping a new horizon for global tourism.
Powered by the Saudi Ministry of Tourism, the inaugural TOURISE Summit will take place 11-13, November 2025 in Riyadh. TOURISE will convene visionaries from government, business, investment, tourism and technology communities to deliver high impact initiatives and transformative deals that will reset the industry and build a tourism sector that is sustainable, equitable, and future-focused.
Physically exclusive and digitally inclusive, TOURISE will ensure broad global participation while providing targeted access to visionaries shaping the future of global tourism. Following the Summit, TOURISE will extend as a year-round platform where bold ideas become real-world solutions.
This is where the next 50 years of tourism are shaped. Together, we are unstoppable.
For more information about TOURISE, visit www.tourise.com and subscribe to the newsletter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250804928537/en/
Contacts
For media inquiries please contact: media@tourise.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom